Stock CDTX CIDARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Cidara Therapeutics, Inc.

Equities

CDTX

US1717571079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
12.29 USD +19.90% Intraday chart for Cidara Therapeutics, Inc. -14.91% -22.61%
Apr. 24 Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset DJ
Apr. 23 Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset
DJ
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
AQ
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
AQ
Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket
MT
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q4 Revenue $17.6M
MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
AQ
Cidara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cidara Therapeutics to Effect 1-for-20 Reverse Stock Split
MT
Cidara Therapeutics Announces Reverse Stock Split
AQ
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge
DJ
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
AQ
North American Morning Briefing : Focus Turns to -2-
DJ
North American Morning Briefing : Stocks Set for -2-
DJ
CIDARA THERAPEUTICS TO PRESENT PRECLINCAL DATA ON MULTIPLE NOVEL DRUG-FC CONJUGATE CANDIDATES AT AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2024
AQ
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
AQ
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
AQ
North American Morning Briefing : Microsoft Kicks Off Big Tech Bonanza
DJ
Cidara Therapeutics Says UK Regulator Approved Invasive Candidiasis Treatment
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CDTX Stock
  4. News Cidara Therapeutics, Inc.